Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial by Nesaretnam, Kalanithi et al.
RESEARCH ARTICLE Open Access
Effectiveness of tocotrienol-rich fraction combined
with tamoxifen in the management of women
with early breast cancer: a pilot clinical trial
Kalanithi Nesaretnam
1*, Kanga Rani Selvaduray
1, Ghazali Abdul Razak
1, Sheela Devi Veerasenan
1, Patricia A Gomez
2
Abstract
Introduction: Basic research has indicated that tocotrienols have potent antiproliferative and proapoptotic effects
that would be expected to reduce the effect of breast cancer.
Methods: We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant
tocotrienol therapy in combination with tamoxifen for 5 years in women with early breast cancer. Two-hundred-
forty women, aged between 40 and 60 years, with either tumor node metastases (TNM) Stage I or II breast cancer
and estrogen receptor (ER)-positive tumors were nonrandomly assigned to two groups. The intervention group
received tocotrienol-rich fraction (TRF) plus tamoxifen, whereas the control group received placebo plus tamoxifen,
for 5 years.
Results: During the 5 years of the study, eight patients died of breast cancer, whereas in 36 patients, a local or
systemic recurrence developed. Five-year breast cancer-specific survival was 98.3% (95% confidence interval (CI),
95.9% to 100%) in the intervention group and 95% (95% CI, 91.1% to 98.9%) in the control group, whereas the
5-year disease-free survival was 86.7% (95% CI, 80.6% to 92.8%) and 83.3% (95% CI, 76.6% to 90.0%), respectively.
Risk of mortality due to breast cancer was 60% (HR, 0.40; 95% CI, 0.08 to 2.05) lower in the intervention group
versus the controls after adjustment for age, ethnicity, stage, and lymph node status, but this was not statistically
significant. Adjuvant TRF therapy was not associated with breast cancer recurrence (HR, 0.84; 95% CI, 0.43 to 1.65).
Conclusions: From the current study, no association seems to exist between adjuvant tocotrienol therapy and
breast cancer-specific survival in women with early breast cancer.
Trial registration: ClinicalTrials.gov Identifier: NCT01157026.
Introduction
Vitamin E is a potent antioxidant classified into sub-
groups of tocopherols and tocotrienols. In most food
sources, tocopherols are more prevalent than tocotrie-
nols. Palm oil is a particularly rich source of a-, g-, and
δ-tocotrienol [1,2]. Previous studies reported that indivi-
dual tocopherols and tocotrienols exhibit different
potencies in suppressing tumor cell growth and indu-
cing apoptosis in neoplastic mammary epithelial cells
[3,4]. Administrations of a-a n dg-tocotrienol, and not
a-tocopherol, have shown a life-prolonging effect in
mice from transplanted tumors [5]. Tocotrienols also
were found to suppress the growth of human breast and
colorectal cancer cells [6-9], but a-tocopherol was not.
These effects of tocotrienols may be explained through
mechanisms such as antiangiogenesis, antiproliferation,
induction of apoptosis, and improving immunologic
functions [10].
Because tocotrienols are more potent than tocopherols
[6-8,11,12], we hypothesize that tocotrienol intake may
be associated with improved survival and lower recur-
rence in patients with early breast cancer. We investi-
gated the effectiveness of TRF in combination with
tamoxifen compared with placebo with tamoxifen as
adjuvant therapy in improving breast cancer-specific sur-
vival in women with estrogen receptor (ER)-positive
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2 (early) breast cancer. It should also be noted that toco-
trienols with tamoxifen have shown a synergistic inhibi-
tory effect on the proliferative rate and growth of breast
cancer cells in vitro [11].
Materials and methods
Study design
We conducted a double-blinded, placebo-controlled trial
for 5 years comparing tocotrienol-rich fraction (TRF)
plus tamoxifen with placebo plus tamoxifen in women
with early breast cancer. In total, 240 women with early
breast cancer were assigned to two treatment groups by
nonrandom allocation. The intervention group was given
TRF plus tamoxifen (n = 120), whereas the control group
was given placebo plus tamoxifen (n = 120). The primary
end point was breast cancer-specific survival, defined as
the time from allocation to treatment group to death of
breast cancer. Breast cancer-specific survival was chosen
as primary outcome based on overall health-protective
effects conferred by the multiple functions of tocotrie-
nols, including anticancer, anti-inflammatory, and antiox-
idant effects. The secondary end points included
recurrence (either local or systemic), biochemical para-
meters, liver function, and plasma levels of vitamin E.
Study population
In total, 240 patients treated in Kuala Lumpur Hospital,
Malaysia, were recruited between November 2001 and
November 2002. Only women with histologically con-
firmed primary breast cancer and estrogen receptor-posi-
tive tumors (determined with an immunohistochemistry
test with a 10% cut-off point for positivity) were recruited
into the study. Other criteria for eligibility included age
of 40 to 60 years at the start of the tamoxifen therapy
and an Eastern Cooperative Oncology Group perfor-
mance status of 0, 1, or 2 (scored on a scale of 0 to 5,
with lower scores indicating better function) [13].
Criteria for exclusion were the concurrent use of investi-
gational drugs and estrogen-receptor status negative or
unknown.
Treatment program
Patients were blinded to the treatment that they received.
Both the TRF and placebo drugs were prepared and sup-
plied by Hovid Sdn. Bhd., Malaysia. The TRF drug was
prepared in a capsule form at a dose of 200 mg per cap-
sule. The placebo drug, which contained soy oil without
tocotrienols, had an appearance and taste similar to that
of the TRF drug. Patients were allocated to two treatment
groups that received a daily dose of two capsules (one
active TRF 200-mg capsule or placebo capsule, along
with a tamoxifen 20-mg tablet). Patients were instructed
to take the two capsules together at approximately the
same time each day. Trial treatment continued for
5 years from the date of recruitment. Patients were
assessed every 3 months for compliance by collection of
bottles containing capsules and random visits to their
homes by the research staff.
The assessors were also blinded to the treatment
received by the trial patients. Baseline assessment included
demographic and clinical profiles, such as age, race,
breast-cancer stage, and involvement of lymph nodes.
Clinical evaluations, routine blood tests for hematology,
and blood chemistry assessment were performed every 6
months during year 1 and annually thereafter. Patients
were monitored for compliance with follow-up, whereby
those who defaulted were contacted and, when necessary,
new appointment dates given. Patients underwent several
biochemical screening tests, such as complete blood count
(CBC), differential count, and liver-function tests. These
biochemical parameters were also used to determine
the health conditions of the patients. Mammography was
performed annually throughout the study. Both local and
systemic recurrence of disease was defined pathologically
or on the basis of clinical or radiologic findings, and recur-
rences were dated at the time they were first detected.
Additionally, all deaths recorded in this study were con-
firmed as due to breast cancer. The ethical clearance for
this study was approved by the Research and Ethics Com-
mittee of the Ministry of Health, Malaysia (National Medi-
cal Research Register: Research Registration ID: 5399 S1).
Written informed consent was obtained from all patients.
Vitamin E extraction from blood plasma and HPLC
analysis
Blood samples collected in heparinized tube were spun at
2,000 rpm for 10 minutes at room temperature. The
plasma was isolated from the sedimented red blood cells
and transferred into a sterile 1.5-ml centrifuge tube. After
this, 500 μl of the plasma was then added to a tube con-
taining 0.5 ml of 0.5% NaCl and ethanol. Then 400 μlo f
hexane was added into this tube. The mixture was shaken
vigorously for an hour by using a mini-shaker. The tubes
were then spun at 3,000 rpm for 10 minutes at room tem-
perature. After centrifugation, the clear hexane phase was
transferred carefully into a clean vial and blow-dried
under nitrogen gas. An aliquot of the lipid sample was
reconstituted in 500 μl hexane. Then 10 μl of the sample
and a standard solution mixture of a-tocopherols, a-, g-,
and δ-tocotrienols was also injected accordingly into a
HPLC system. The excitation wavelength and emission
wavelength of the fluorescence detector were set at 295
and 325 nm, respectively. The mobile phase was hexane-
isopropyl alcohol (99.5/0.5, vol/vol) with a flow rate of
2 ml/min. The peak areas of the components in the sam-
ple were compared with those of the standards and were
used for quantitative calculation.
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The sample size was calculated under the assumption of
a5 - y e a rd i s e a s e - s p e c i f i cs u r v i v a lo f9 5 %i nt h et a m o x i -
fen-plus-placebo group and the detection of a difference
of 5% in the 5-year disease-specific survival rate. These
assumptions necessitated the enrollment of 240 women.
Categoric variables were described in proportion and
compared by using the c
2 test, whereas continuous vari-
ables were described in means and compared by using
the t test. The analysis was based on the intention-to-
treat principle. Kaplan-Meier analysis was used to esti-
mate breast cancer-specific survival and disease-free
survival, comparing the treatment versus the control
group. Survival curves were compared by using the log-
rank test. Cox regression analysis was used to compute
crude hazard ratios to determine the association between
TRF-plus-tamoxifen intake and breast cancer-specific
death as well as recurrence of breast cancer, compared
with the intake of placebo plus tamoxifen, which is the
reference group. This model was subsequently adjusted
for age (continuous), TNM stage (1 or 2), ethnicity
(Malay, Chinese, Indian), and lymph node involvement
(yes, no). Two-sided P values lower than 0.05 and HR
with 95% confidence interval (CI) which does not include
1.00 were considered statistically significant. Data
obtained during the study were processed by using SPSS
for Windows (Version 18.0; SPSS Inc., Chicago, IL).
Results
Patient characteristics
T h em e d i a nd u r a t i o no ff o l l o w - u pw a s6 0m o n t h s ,
with complete follow-up of all patients who complied
with their treatment throughout the study. Eight
patients (two in the intervention group versus six in
the control group) had died of breast cancer, and 36
patients (16 in the intervention group versus 20 in
the control group) had local or systemic recurrence.
Figure 1 shows the CONSORT diagram of the study.
The groups were well balanced with respect to demo-
graphic and tumor characteristics (Table 1). Approxi-
mately 61% of patients in the TRF-plus-tamoxifen
group and 49% of patients in the placebo-plus-tamoxi-
fen group were in TNM stage 1 of breast cancer,
whereas 39% of patients in the TRF-plus-tamoxifen
g r o u pa n d5 1 %i nt h et a m o x i f e ng r o u pw e r ei nT N M
stage 2 (P = 0.07). A total of 58% of patients in the
TRF-plus-tamoxifen group and 63% of patients in the
placebo-plus-tamoxifen group showed involvement of a
lymph node (P = 0.51). The average number of lymph
nodes involved among these patients was 1.5 and 1.1,
respectively (P = 0.15).
Based on Kaplan-Meier analysis, 5-year breast cancer-
specific survival in the TRF-plus-tamoxifen group was
98.3% (95% CI, 95.9% to 100%) compared with 95%
(95% CI, 91.1% to 98.9%) in the placebo-plus-tamoxifen
group (Figure 2). P for the log-rank test was 0.15. The
5-year recurrence-free survival was 86.7% (95% CI,
80.6% to 92.8%) and 83.3% (95% CI, 76.6% to 90.0%),
respectively. P for log-rank test was 0.47.
The crude hazard ratio for breast cancer-specific death
in the TRF-plus-tamoxifen group compared with pla-
cebo-plus-tamoxifen group was 0.33 (95% CI, 0.07 to
1.61) (Table 2). After adjustment for age, ethnicity,
stage, and lymph node status, the multivariate HR was
0.40 (95% CI, 0.08 to 2.05) and statistically was not sig-
nificant. Compared with placebo intake, intake of toco-
trienol by patients with stage 1 or stage 2 breast cancer,
and estrogen receptor-positive tumor treated with
tamoxifen, is associated with a not statistically signifi-
cant (P = 0.27) 60% lower risk of mortality, after adjust-
ment for age, ethnicity, stage, and lymph node status.
The multivariate HR for local or systemic recurrence
in the TRF-plus-tamoxifen group compared with the
placebo-plus-tamoxifen group was 0.84 (95% CI, 0.43
to 1.65).
Biochemical parameters in study population
The mean values of the results from the biochemical
screening tests on day 0, year 1, 2, 3, 4, and 5 of TRF-
plus-tamoxifen supplemented group and placebo-plus-
tamoxifen supplemented group are shown in Table 3.
The biochemical parameters measured did not exhibit
any significant changes from the results obtained before
the start of the study for both TRF-plus-tamoxifen and
placebo-plus-tamoxifen groups.
Liver-function tests
The purpose of liver-function tests is to study the toler-
ance of the supplement. The mean values of the results
from the liver-function tests on day 0, year 1, 2, 3, 4,
and 5 of TRF-plus-tamoxifen supplemented group and
placebo-plus-tamoxifen supplemented group are shown
in Table 4.
Liver-function tests (total protein, albumin, and total
bilirubin) showed insignificant values for before the start
and at completion of the study for the TRF-plus-tamoxi-
fen supplemented group and the placebo-plus-tamoxifen
supplemented group. Liver-function tests such as alka-
line phosphatase and alanine transaminase showed high
standard-deviation (SD) values. This is due to the collec-
tion of samples from patients after the chemotherapy
session.
High levels of vitamin E in plasma of patients
supplemented with TRF
Plasma samples obtained from patients were analyzed by
using HPLC to quantify the concentrations of vitamin E
in plasma (Figure 3).
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Figure 1 Flow diagram of the progress through the phases of the parallel trials of two groups (enrolment, intervention allocation,
follow-up, and data analysis).
Table 1 Baseline demographic and tumor profile of 240 breast cancer patients with estrogen receptor-positive tumors
Tocotrienol + tamoxifen
(n = 120)
Tamoxifen only
(n = 120)
P value
Age (years) 48.5 (5.2) 49.1 (5.9) 0.30
Ethnicity:
Malay 50.0 (60) 46.7 (56) 0.61
Chinese 30.0 (36) 37.5 (45) 0.22
Indian 20.0 (24) 15.8 (19) 0.40
Stage of breast cancer: 0.07
1 60.8 (73) 49.2 (59)
2 39.2 (47) 50.8 (61)
Involvement of lymph node:
Yes 58.3 (70) 62.5 (75) 0.51
Number of lymph nodes involved
a 1.5 (3.1) 1.1 (1.9) 0.15
Continuous variables are expressed as means (standard deviations), and categoric variables, as percentages (numbers).
aIncludes only patients with lymph node
involvement.
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blood of patients from both groups increased signifi-
cantly (P < 0.05) after the 5-year period compared with
d a y0( F i g u r e3 ) .T h ea-tocopherol, a-, g-, and δ-toco-
trienol concentrations increased significantly (P < 0.05)
in patients who received TRF plus tamoxifen as com-
pared with placebo plus tamoxifen (Figure 3).
However, the concentrations of tocotrienols in the pla-
cebo group after the 5-year period remained the same,
and the amounts did not differ significantly (P > 0.05) as
compared with those at day 0.
Discussion
In our current pilot study, we found no protective asso-
ciation between tocotrienol intake and breast cancer-
related mortality or recurrence in patients with early
breast cancer. Tamoxifen-alone and TRF-plus-tamoxifen
supplementation also did not change the blood para-
meters of patients before the start and upon completion
of the study.
The risk of dying of breast cancer seems to be reduced
by approximately 60% in patients receiving a combina-
tion of tocotrienol and tamoxifen compared with patients
receiving placebo and tamoxifen. However, this was not
statistically significant (P = 0.27). Previous studies carried
out in our laboratory showed that tocotrienols inhibited
growth and proliferation of breast cancer cells [6-8].
Another study reported that the anticarcinogenic prop-
erty of tocotrienols in synergy with tamoxifen is more
potent than tamoxifen alone [11]. Recently we also
Figure 2 Breast cancer-specific survival in intervention versus control group.
Table 2 Tocotrienol intake and risk of breast cancer-specific death/recurrence in women with early breast cancer and
estrogen receptor-positive tumors receiving tamoxifen
Type of treatment received along with tamoxifen
Placebo (n = 120) Tocotrienol (n = 120)
Breast cancer-related death
Number of patients (n (%)) 6 (5.0) 2 (1.7)
Crude hazard ratio 1.00 0.33 (95% CI, 0.07 to 1.61)
Adjusted hazard ratio
a 1.00 0.40 (95% CI, 0.08 to 2.05)
Local/systemic recurrence of breast cancer
Number of patients (n (%)) 20 (16.7) 16 (13.3)
Crude hazard ratio 1.00 0.80 (95% CI, 0.41 to 1.54)
Adjusted hazard ratio
a 1.00 0.84 (95% CI, 0.43 to 1.65)
aAdjusted for age (continuous), ethnicity (Malay, Chinese, Indian), TNM stage (stage 1, stage 2), and lymph node involvement (yes, no).
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Parameters Range Day 0 Year 1 Year 2 Year 3 Year 4 Year 5
Group (Mean ± SD)
White blood count
Placebo + Tamoxifen 4-11 6.29 ± 2.09 6.77 ± 1.79 7.06 ± 2.07 7.11 ± 2.37 7.22 ± 7.22 7.36 ± 7.36
TRF + Tamoxifen (×10
9/L) 5.86 ± 2.01 5.81 ± 1.59 5.86 ± 1.78 6.28 ± 1.92 6.33 ± 1.76 6.46 ± 1.62
Red blood count
Placebo + Tamoxifen 3.8-5.8 4.48 ± 0.48 4.46 ± 0.44 4.41 ± 0.40 4.49 ± 0.46 4.43 ± 0.54 4.55 ± 0.53
TRF + Tamoxifen (×10
12/L) 3.95 ± 0.81 4.24 ± 0.41 4.27 ± 0.34 4.28 ± 0.34 4.27 ± 0.45 4.28 ± 0.40
Hemoglobin
Placebo + Tamoxifen 11.5-16.5 12.49 ± 1.28 12.40 ± 1.18 12.63 ± 1.16 12.66 ± 0.96 12.61 ± 0.92 12.70 ± 0.96
TRF + Tamoxifen (g/dl) 11.79 ± 2.48 12.71 ± 1.13 12.67 ± 0.93 12.72 ± 0.99 12.65 ± 1.27 12.77 ± 1.01
Hematocrit
Placebo + Tamoxifen 37-47 38.90 ± 3.27 38.34 ± 2.56 38.53 ± 2.82 38.48 ± 2.68 37.44 ± 8.69 38.69 ± 3.06
TRF + Tamoxifen (%) 35.51 ± 7.30 38.76 ± 4.31 37.96 ± 4.32 38.68 ± 2.97 38.36 ± 4.19 38.63 ± 3.27
Lymphocyte
Placebo + Tamoxifen 20-45 33.03 ± 6.62 33.37 ± 6.21 34.30 ± 8.13 35.19 ± 6.27 34.82 ± 8.32 35.48 ± 7.20
TRF + Tamoxifen (%) 31.42 ± 8.35 33.79 ± 9.41 33.22 ± 8.58 34.65 ± 8.68 34.59 ± 6.63 36.39 ± 9.58
Platelet count
Placebo + Tamoxifen 150-400 221.52 ± 60.59 221.48 ± 46.09 222.19 ± 61.39 238.10 ± 61.63 250.00 ± 61.87 260.10 ± 57.85
TRF + Tamoxifen (×10
9/L) 221.16 ± 89.81 217.89 ± 50.74 217.63 ± 58.52 226.13 ± 49.69 247.74 ± 76.05 243.07 ± 61.02
The mean values of the results from the biochemical screening tests on day 0 and years 1, 2, 3, 4, and 5 of tocotrienol-rich fraction (TRF)-plus-tamoxifen
supplemented group and placebo-plus-tamoxifen supplemented group.
Table 4 Liver-function tests
Parameters Range Day 0 Year 1 Year 2 Year 3 Year 4 Year 5
Group (Mean ± SD)
Total protein
Placebo + Tamoxifen 66-87 76.68 ± 5.04 76.72 ± 5.89 77.56 ± 5.12 77.32 ± 4.55 75.48 ± 5.28 77.08 ± 5.10
TRF + Tamoxifen g/L 76.03 ± 4.71 76.31 ± 5.33 76.41 ± 5.07 76.82 ± 4.55 77.08 ± 4.65 76.54 ± 4.82
Albumin
Placebo + Tamoxifen. 35-50 41.48 ± 3.78 41.72 ± 3.80 40.84 ± 7.14 42.60 ± 4.29 41.48 ± 3.81 41.40 ± 7.46
TRF + Tamoxifen g/L 41.28 ± 3.24 41.36 ± 3.69 41.05 ± 3.64 42.00 ± 4.13 41.69 ± 4.46 41.92 ± 4.07
Total bilirubin
Placebo + Tamoxifen < 21 7.80 ± 3.81 7.80 ± 4.17 8.40 ± 3.58 9.16 ± 3.98 8.12 ± 3.70 8.72 ± 4.09
TRF + Tamoxifen μM 8.00 ± 3.94 7.74 ± 3.70 7.74 ± 3.88 8.15 ± 4.63 7.95 ± 3.72 8.16 ± 3.89
Alkaline phosphatase
Placebo + Tamoxifen 42-98 65.08 ± 17.09 63.88 ± 15.21 64.56 ± 19.58 66.80 ± 17.14 62.12 ± 15.14 65.28 ± 18.92
TRF + Tamoxifen U/L 66.67 ± 18.55 62.51 ± 20.15 66.18 ± 20.41 64.74 ± 18.44 67.79 ± 20.06 68.42 ± 19.92
Alanine transaminase
Placebo + Tamoxifen < 32 28.28 ± 22.69 34.04 ± 50.06 23.28 ± 13.87 27.72 ± 25.74 32.28 ± 48.75 24.28 ± 18.16
TRF + Tamoxifen U/L 32.18 ± 29.63 32.85 ± 18.93 31.69 ± 20.55 32.13 ± 28.04 29.77 ± 15.25 28.79 ± 15.14
The mean values of the results from the liver-function tests on day 0 and years 1, 2, 3, 4, and 5 of tocotrienol-rich fraction (TRF)-plus-tamoxifen supplemented
group and placebo-plus-tamoxifen supplemented group.
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bit breast cancer cell growth, in which the effects are
mediated by binding to the ERb and inducing the expres-
sion of specific genes containing estrogen-responsive ele-
ment (ERE) sequences in their promoter [14].
Our results showed that the TRF-plus-tamoxifen supple-
mented group had significantly higher concentrations of
a-tocopherol and a-, g-, and δ-tocotrienols in the plasma
of the breast cancer patients. Plasma a-tocopherol levels
were much higher than those of any other tocotrienol iso-
mers. This result supports the findings reported by [15],
who reasoned that a-tocopherol transfer protein (a-TTP),
together with the tocopherol-associated proteins (TAP)
are responsible for the endogenous accumulation of nat-
ural a-tocopherol.
Concentrations of the micronutrient in blood plasma
revealed that a-tocotrienols had the highest absorption,
followed by g-a n dδ-tocotrienols, in all individuals sup-
plemented with tamoxifen and TRF at the end of study,
as compared with placebo and basal concentrations of
the micronutrients. Although the a-TTP that binds the
vitamin E isoforms via low-density lipoprotein (LDL)
have a much lower capacity to transport tocotrienols, it
has been previously reported that orally supplemented
tocotrienol results in plasma tocotrienol concentration
in the range of 3 μM [16].
In our study, liver function was not altered by the
supplementation of tamoxifen in combination with TRF.
It seems that this combination is well tolerated.
The major strength of this study is that it is the first
experimental study that was conducted to investigate the
effect of TRF on survival of patients with early breast
cancer. Furthermore, we had a complete follow-up of all
of our patients at every point of the assessment, and they
also complied well with the treatment assigned to them.
The lack of randomization is a limitation in this study.
However, the two groups were balanced with respect to
demographic and tumor characteristics. In addition, a
notable weakness in this study is that we had a relatively
small sample size with a low number of outcomes, possi-
bly resulting from using breast cancer-specific death as
our primary outcome, leading to a low power to detect
statistically significant differences in the outcomes
between the two groups.
Conclusions
Results from this study are not sufficient to indicate a sig-
nificant association between adjuvant tocotrienol therapy
and breast cancer survival in women with early breast can-
cer. It is important to note that accruing evidence suggests
that tocotrienols have anticancer effects. Moreover,
tamoxifen and tocotrienol in vitro have demonstrated
synergy. Although a 60% lower mortality occurred in the
intervention group, this result was not statistically signifi-
cant. Hence, a large randomized trial is certainly war-
ranted in the near future to establish whether tocotrienol
adjuvant therapy can significantly improve recurrence or
mortality or both.
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Figure 3 The a-tocopherol, a-, g-, and δ-tocotrienol concentrations increased significantly after 5 years for the TRF-supplemented
group.* P < 0.05.
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